ArticleHeliyon2024
Multi-objective liver cancer algorithm: A novel algorithm for solving engineering design problems.
Article in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 35 citations in OpenAlex.
- A Hybrid Nonlinear Greater Cane Rat Algorithm with Teaching-Learning-Based Optimization for Global Optimization and Constrained Engineering Applications.Biomimetics (Basel, Switzerland) · 2026Article
- A synergistic enhancement of the Ivy algorithm for GAN-based imbalanced classification.Scientific reports · 2025Article
- A Mobile Wireless Sensor Coverage Optimization Method for Bridge Monitoring.Sensors (Basel, Switzerland) · 2025Article
- Multi objective elk herd optimization for efficient structural design.Scientific reports · 2025Article
- Differences in brain spindle density during sleep between patients with and without type 2 diabetes.Computers in biology and medicine · 2025Article
- A Gaussian convolutional optimization algorithm with tent chaotic mapping.Scientific reports · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 6 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research introduces the Multi-Objective Liver Cancer Algorithm (MOLCA), a novel approach inspired by the growth and proliferation patterns of liver tumors. MOLCA emulates the evolutionary tendencies of liver tumors, leveraging their expansion dynamics as a model for solving multi-objective optimization problems in engineering design. The algorithm uniquely combines genetic operators with the Random Opposition-Based Learning (ROBL) strategy, optimizing both local and global search capabilities. Further enhancement is achieved through the integration of elitist non-dominated sorting (NDS), information feedback mechanism (IFM) and Crowding Distance (CD) selection method, which collectively aim to efficiently identify the Pareto optimal front. The performance of MOLCA is rigorously assessed using a comprehensive set of standard multi-objective test benchmarks, including ZDT, DTLZ and various Constraint (CONSTR, TNK, SRN, BNH, OSY and KITA) and real-world engineering design problems like Brushless DC wheel motor, Safety isolating transformer, Helical spring, Two-bar truss and Welded beam. Its efficacy is benchmarked against prominent algorithms such as the non-dominated sorting grey wolf optimizer (NSGWO), multiobjective multi-verse optimization (MOMVO), non-dominated sorting genetic algorithm (NSGA-II), decomposition-based multiobjective evolutionary algorithm (MOEA/D) and multiobjective marine predator algorithm (MOMPA). Quantitative analysis is conducted using GD, IGD, SP, SD, HV and RT metrics to represent convergence and distribution, while qualitative aspects are presented through graphical representations of the Pareto fronts. The MOLCA source code is available at: https://github.com/kanak02/MOLCA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.